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Na+,K+-ATPaseDe novo mutations in ATP1A3, the gene encoding the α3-subunit of Na+,K+-ATPase, are associated with
the neurodevelopmental disorder Alternating Hemiplegia of Childhood (AHC). The aim of this study was to
determine the functional consequences of six ATP1A3 mutations (S137Y, D220N, I274N, D801N, E815K, and
G947R) associated with AHC. Wild type and mutant Na+,K+-ATPases were expressed in Sf9 insect cells using
the baculovirus expression system. Ouabain binding, ATPase activity, and phosphorylation were absent in
mutants I274N, E815K andG947R.Mutants S137Y andD801Nwere able to bind ouabain, although thesemutants
lackedATPase activity, phosphorylation, and theK+/ouabain antagonism indicative ofmodiﬁcations in the cation
binding site. Mutant D220N showed similar ouabain binding, ATPase activity, and phosphorylation to wild type
Na+,K+-ATPase. Functional impairment of Na+,K+-ATPase inmutants S137Y, I274N, D801N, E815K, and G947R
might explain why patients having these mutations suffer from AHC. Moreover, mutant D801N is able to bind
ouabain, whereasmutant E815K shows a complete loss of function, possibly explaining the different phenotypes
for these mutations.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Alternating Hemiplegia of Childhood (AHC) is a rare, severe
neurodevelopmental disorder, reported for the ﬁrst time in 1971 by
Verret and Steele [1]. The incidence of AHC has been estimated at 1 in
1,000,000 births, with disease usually ensuing within the ﬁrst six
months [2]. AHC is characterized by episodes of hemiplegia on alternat-
ing sides of the body [3], which can last froma fewminutes up to several
days. Other symptoms that can occur during AHC episodes include
pallor, abnormal eye movements, movement disorders, dystonia and
severe cognitive impairment [4]. Patient studies have reported different
provoking factors: water exposure, extreme temperatures, physical
activity, bright light, and stress [5]. Falling asleep leads to disappearance
of all symptoms, although they may return after waking up. The exact
mechanism of disease is unknown, although treatmentwith Flunarizine
(a Ca2+ inﬂux inhibitor speciﬁc for vascular smooth muscle and
neurons) has been reported to reduce symptoms [6,7]. However, the
effectiveness and long-term effects of this treatment are unknown [5].logy and Toxicology, Radboud
Nijmegen, The Netherlands.
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sel),AHC was recently linked to de novo mutations in ATP1A3, the gene
encoding the Na+,K+-ATPase α3 subunit [8,9]. Most mutations are
located in or near the ten transmembrane domains of Na+,K+-ATPase.
Interestingly, two mutations (D801N and E815K) found in 66% of the
AHC patients show differences with regard to disease severity, where
E815K has been associated with a more severe phenotype [10]. Previ-
ously, ATP1A3 mutations were identiﬁed in patients suffering from
Rapid-Onset Dystonia Parkinsonism (RDP) [11]. Until now, there
has been only one mutation that is reported in AHC and RDP cases
(D923N), indicating minor overlap between both diseases [12–14].
Na+,K+-ATPase plays a major role in maintaining the electrochemi-
cal gradient across the plasmamembrane. Theα-subunit is the catalytic
component of this transport protein, which together with theβ-subunit
forms a functional transporter enzyme, in some tissues accompanied
by a third or gamma subunit. In humans, four different isoforms of the
α-subunit exist. Three of these isoforms are expressed in the human
brain:α1 inmultiple cell types due to its ubiquitous expression, includ-
ing neurons and glial cells, α2 predominantly in astrocytes, and α3 in
peripheral and central nervous system neurons [15,16]. When catalyti-
cally active, Na+,K+-ATPase transports three sodium ions out of the
cell and two potassium ions into the cell, a process fueled by hydrolysis
of one molecule ATP [15]. During this catalytic cycle, Na+,K+-ATPase is
present in the E1 or the E2 conformation, depending on the association
of either Na+ or K+ to the ion binding sites (Fig. 1A). The presence
of both ATP and Na+ is necessary for the phosphorylation of the
protein in the E1 state, which leads to a conformational change into
Fig. 1. (A) Albert-Post scheme of the reaction cycle of Na+,K+-ATPase. Transport of Na+ and K+ across the cell membrane is accomplished by a series of conformational changes of the
Na+,K+-ATPase based on binding of either Na+ or K+, leading to phosphorylation or dephosphorylation, changing the afﬁnity of the enzyme for its ligands. During each reaction cycle,
three Na+ ions are transported out of the cell, in return transporting two K+ ions into the cell. This process requires the hydrolysis of ATP, to drive the transition into the high energy E1P
and E2P states. Binding of DLCs, well-known inhibitors of Na+,K+-ATPase function, is only possible in the E2P or E2 state. (B) Crystal structure of the Na+,K+-ATPase heteromer in the E2
state (PDB: 3KDP) [32], with the location of the six mutations studied here highlighted by spheres. Note how ﬁve mutations are located in or near transmembrane regions, whereas
mutant D220N is located in the large cytosolic loop between transmembrane domains two and three. The six residues are conserved between the alpha 1 and alpha 3 isoforms, making
the alpha 1 crystal structure suitable for representation. Blue is alpha subunit, red is beta subunit, green is gamma subunit, and yellow is used to highlight the mutations studied here.
Figure was created using YASARA software.
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transition to the E2P state, Na+ is released out of the cell, followed
by binding of K+, which initiates dephosphorylation of the protein
and transition into the K+-bound E2 state [17]. Binding of ATP drives
the protein back into the E1 state, completing the catalytic cycle.
The effect of ATP1A3 mutations on protein functionality is hardly
studied. Moreover, whether different phenotypes can be linked to
speciﬁc mutations is not known. In this study, we determined the
functional consequences of six de novo ATP1A3 mutations (S137Y,
D220N, I274N, D801N, E815K, and G947R, see Fig. 1B) in order to
relate protein functionality to AHC phenotypes.
2. Materials and methods
2.1. The Gateway system
The desired mutations were obtained by ﬁrst performing two PCRs
(A and B) on human Na+,K+-ATPase alpha 3 wild type cDNA using
either a 5′ or 3′ primer in combination with a primer containing the
desired mutation, resulting in two different fragments that were subse-
quently combined for a ﬁnal PCR (C) using only the 5′ and 3′ primers,
allowing annealing of the two fragments (A and B) containing the
desired mutation. Next, the obtained mutant Na+,K+-ATPase α3 was
cloned into an entry vector using BP Clonase II enzyme according
to the manufacturer's instructions (Invitrogen). After a successfultransformation of entry clones into DH5α cells and overnight selection,
colonies were grown overnight in liquid medium and subsequently
isolated using the GenElute™mini-prep isolation kit (Sigma-Aldrich).
Following a restriction analysis, full length sequencing of the different
constructs was performed to check for successful mutagenesis. Subse-
quently, the entry clones were combined with an empty destination
vector already containing the β1 gene (ATP1B1) using LR Clonase II
(Invitrogen), resulting in an expression clone containing the desired
mutation. As a negative control, an expression clone containing YFP in
combination with the β1 subunit was used for mock transfection.
2.2. Generation of recombinant viruses
The expression clones, generated using the Gateway system,
were transformed to competent DH10Bac Escherichia coli cells
(Life Technologies, Breda, The Netherlands) harboring the baculovirus
genome (bacmid) and a transposition helper plasmid. Upon transposi-
tion between the Tn7 sites present in both the bacmid and the expres-
sion clone, recombinant bacmids were selected and isolated [18].
Subsequently, the obtained bacmids were transfected to Sf9 insect cells
using Cellfectin reagent (Life Technologies, Breda, The Netherlands).
After a 6-day period, recombinant baculoviruses were harvested and
used to infect fresh Sf9 cells at a multiplicity of infection of 0.1. After
another 6 days of culture of infected Sf9 cells, ampliﬁed baculoviruses
were harvested [19].
Fig. 2.Western blot of Na+,K+-ATPase α- and β-subunits for six different Sf9 membrane
preparations. Membranes (20 μg) were run on a 10% SDS-PAGE gel and transferred to a
PVDF membrane. The presence of α- and β-subunits was detected using antibodies
C356-M09 and C385-M77, respectively [20,21].
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Sf9 cells grown at 27 °C in T175 and later in 500mL shaking ﬂasks in
Xpress medium (Sigma, Bornem, Belgium) were infected at a density of
1.5 · 106 cells·mL−1 in the presence of 1% (v/v) ethanol, as described
before [20]. After three days of infection, cells were harvested by centri-
fugation at 2000×g for 5min. Then, the pelleted cells were resuspended
at 0 °C in a 250mM saccharose, 2.0mMEDTA and 20mMHEPES/Tris at
pH 7.0 buffer. Sonication was performed for 30 s at 80 W prior to
centrifugation at 10,000 ×g at 4 °C for 30 min, followed by centrifuga-
tion of the resulting supernatant at 100,000 ×g at 4 °C for 1 h. The
pelleted membranes were resuspended in the buffer mentioned above,
homogenized, and stored at−20 °C before use in biochemical studies.
2.4. Western blotting
Approximately 20 μg of membranes were treated with SDS-PAGE
solubilization buffer overnight at room temperature before loading on
a 10% polyacrylamide gel, as described previously [21]. After separation,
the proteins were transferred to a polyvinylidene ﬂuoride membrane
and subsequently blocked in 5% Elk in TBS-T. Then, α- and β-subunits
were detected using either the G36 (anti-α) or the C385-M77 (anti-β)
antibody [20,21].
2.5. ATPase activity studies
To determine the ATPase activity in Na+ or K+ afﬁnity studies, 20 μL
of membranes was incubated in a ﬁnal volume of 100 μL containing
50 mM Tris–Ac at pH 7.0, 0.1 mM EGTA, 1.25 mM MgCl2, 1.0 mM
Tris-N3, 100 μM of radiolabeled ATP, and 50 mM NaCl or 5.0 mM
KCl and increasing concentrations of either KCl or NaCl. After incubation
of the samples for 30 min at 37 °C, the reaction was stopped by the
addition of 500 μL of 10% (w/v) charcoal in 6% (v/v) trichloroacetic
acid and after 10 min at 0 °C the mixture was centrifuged for 30 s.
Subsequently, 150 μL of the clear supernatant was mixed with 4 mL
OptiFluor before analysis using a liquid scintillation counter to deter-
mine the amount of inorganic phosphate (Pi) formed, a measure for
ATPase activity [22]. The Na+,K+-ATPase speciﬁc activity was deter-
mined by subtracting the amount of Pi formed in the presence of
1.0mMouabain.MaximumATPase valueswere determined bymeasur-
ing the activity in the presence of 50 mM NaCl, 5.0 mM KCl, 1.25 mM
MgCl2 and 0.1 mM ATP at pH 7.0.
2.6. Phosphorylation assay
Sf9membranes were incubated in 60 μLmedium, containing 50mM
Tris–acetic acid (pH 7.0), 1.25 mM MgCl2, 100 mM NaCl and in the
presence or absence of 10 mM KCl. After 30 min preincubation, 10 μL
of 0.6 μM [γ-32P]ATP was added and incubated for 10 s at 0 °C. The
reaction was stopped by adding 5% TCA and (phosphorylated) protein
was collected by ﬁltration through a 0.8 μm membrane ﬁlter. After
repeated washing with ice-cold water the ﬁlters were added to
4 mL OptiFluor and analyzed by liquid scintillation analysis [22].
Phosphorylation was calculated by subtracting the amount of phos-
phate detected (phosphorylated protein) in the presence of KCl from
the amount obtained in the absence of KCl.
2.7. Ouabain binding experiments
Ouabain binding was determined by incubation of approximately
150–200 μg of membranes in the presence of 20 mM histidine,
5.0 mM MgCl2, 5.0 mM H3PO4 at pH 7.0, (varying concentrations of
KCl) and 25 nM of radiolabeled ouabain (Perkin-Elmer, Waltham, MA,
USA) in a ﬁnal volume of 60 μL at room temperature for 2 h. After incu-
bation for 15min on ice, the amount of bound ouabain was determined
by washing the samples through a 0.8 μm ME27 ﬁlter using H2O,retaining the enzyme-bound ouabain. The radioactivity retained
on the ﬁlters was determined in a liquid scintillation counter after
the addition of 4 mL OptiFluor (Canberra Packard, Tilburg, The
Netherlands) [23].
2.8. Data analysis
All data were analyzed using GraphPad Prism 5.02. Statistical
analysis (ANOVA, with Dunnett's post test comparing to mock
values, n ≥ 3 for all experiments and α = 0.05) was performed to
test for differences in maximum ouabain binding, apparent ouabain
afﬁnity, apparent Na+ and K+ afﬁnities, maximum phosphorylation
levels and maximum ATPase activity levels compared to mock. The
Na+0.5 and K+0.5 values were calculated via the Hill equation using
the averaged data and SEM values. The Hill coefﬁcient obtained for
wild type Na+,K+-ATPase was used also for the calculation of the
half-maximum Na+ and K+ concentrations of mutants.
2.9. Analysis of crystal structures
Three different crystal structures representing α1β1 Na+,
K+-ATPase in the E1P–ADP (4HQJ [24]), E2P–ouabain (4HYT [25]),
and E2·2K+·Pi (2ZXE [26]) conformations were used to identify
possible interactions involving the mutations characterized in the
present study. YASARA software (www.YASARA.org) was used to
visualize these crystal structures and identify hydrogen (H\) bond
interaction networks.
3. Results
3.1. Analysis of expression
Six single mutations associated with AHC (S137Y, D220N, I274N,
D801N, E815K, and G947R, see Fig. 1B) were introduced in the α3
subunit of Na+,K+-ATPase. Wild type and mutant Na+,K+-ATPases
were expressed in Sf9 insect cells using the baculovirus expression
system. The membrane fractions of these Sf9 cells were isolated and
used for biochemical characterization. Similar expression levels for
wild type and mutant enzymes were detected byWestern blot analysis
using antibodies against the α- and β-subunits (Fig. 2).
3.2. Mutant D220N is catalytically active
The Na+,K+-ATPase activity of both wild type and mutants was
determined in the presence of 100 μM ATP, 5.0 mM KCl and 50 mM
NaCl. Five mutants did not show ATPase activity different from mock
(Fig. 3). Signiﬁcantly higher ATPase activities were observed for wild
type enzyme and mutant D220N (p b 0.05). The activities of wild type
enzyme (1.2 ± 0.1 μmol Pi mg−1 h−1) and mutant D220N (0.98 ±
0.05 μmol Pi mg−1 h−1) were not signiﬁcantly different. The absence
of ATPase activity for the other mutants indicated that these mutations
result in a catalytically inactive enzyme.
Fig. 3. ATPase activity of mutant and wild type Na+,K+-ATPase. Enzymes were
incubated at 37 °C in the presence of 1.3 mM MgCl2, 0.1 mM EGTA, 2.0 mM
Tris-N3, 50 mM Tris–acetic acid (pH 7.0), 100 μM radiolabeled ATP, 5.0 mM KCl and 50
mMNaCl for 30min. Na+,K+-ATPase activitywas corrected for background by subtracting
mock values. Values are presented as mean ± SEM with N ≥ 3. *p b 0.05 versus mock,
ANOVA with Dunnett's post test.
Fig. 4. Effect of Na+, K+ and ATP on the ATPase activity of wild type and mutant Na+,
K+-ATPase. Enzymes were incubated at 37 °C in the presence of 1.3 mM MgCl2,
0.1 mM EGTA, 2.0 mM Tris-N3, 50 mM Tris–acetic acid (pH 7.0), 50 mM or varying
concentrations of NaCl (A), 5.0 mM or varying concentrations of KCl (B), and 100
μM or varying concentrations of ATP (C) for 30 min. Values are presented as mock
corrected mean ± SEM with N ≥ 3.
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are similar
Next, we determined the effect of Na+, K+ and ATP on the ATPase
activity. Since mutant D220N was the only protein that showed ATPase
activity, these experiments were performed only for this mutant. The
Na+ afﬁnitywas determined bymeasuring ATPase activity at increasing
concentrations of NaCl in the presence of 0.1 mM ATP and 5.0 mM KCl.
ATPase activity increased with increasing Na+ concentration (Fig. 4A),
and no signiﬁcant differences in apparent Na+ afﬁnity were observed
between wild type and the mutant D220N (K0.5 of 11 ± 1 mM and
12 ± 1 mM, respectively).
The K+ afﬁnity was determined by measuring ATPase activity at
increasing concentrations of KCl in the presence of 0.1 mM ATP and
50 mM NaCl. As shown in Fig. 4B, there were no signiﬁcant differences
in apparent K+ afﬁnity between wild type (K0.5 = 0.62 ± 0.1 mM)
and mutant D220N (K0.5 = 0.56 ± 0.1 mM).
The ATP afﬁnity was determined by measuring ATPase activity at
increasing ATP concentrations in the presence of 50 mM NaCl and 5.0
mM KCl. Fig. 4C shows no differences in apparent ATP afﬁnity (K0.5 of
55 ± 19 μM (wild type) and 86 ± 27 μM (D220N)).
3.4. Phosphorylation capacity
One of the features of the Na+,K+-ATPase reaction cycle is
phosphorylation of the protein, forming an acid-stable intermediate.
Both Na+ and ATP are necessary for the conformational change of the
protein from the E2 state to the phosphorylated E2P state. In the absence
of K+ and high levels of Na+, the enzymewill accumulate in this confor-
mation (Fig. 1A). The phosphorylation capacity of all mutants was
determined by measuring the amount of phosphoenzyme (E–P) in the
presence of 100 mM NaCl and 0.1 μM ATP, background-corrected for
the amount of E–P present when 10 mM KCl was added (allowing
dephosphorylation to take place as well). Phosphorylation of mutants
S137Y, I274N, D801N, E815K, and G947R was absent (Fig. 5). Mutant
D220N showed a phosphorylation level of 1.8 pmol E–P mg−1, similar
to wild type enzyme (1.8 pmol E–P mg−1).
3.5. Mutants S137Y, D220N and D801N bind ouabain
The conformational change from E2 to E2P–ouabain via E2P
(backdoor phosphorylation) could be determined in the presence
of 5 mM Pi and increasing concentrations of [3H]-ouabain. Ouabainbinding was observed for wild type Na+,K+-ATPase and three
mutants: S137Y, D220N, and D801N (Fig. 6A). The other three mutants
(I274N, E815K and G947R) showed no ouabain binding. Mutant D801N
showed an increase in maximum ouabain binding compared to wild
type enzyme (6.6 pmol mg−1 versus 1.5 pmol mg−1). Mutant S137Y
showed a decreased EOmax (1.0 pmol mg−1), whereas mutant D220N
exhibited ouabain binding capacity equal to wild type enzyme
(1.5 pmol mg−1). Calculated ouabain afﬁnities (Kd) of mutants and
wild type enzyme were not signiﬁcantly different.
Fig. 5. ATP phosphorylation level of wild type and mutant Na+,K+-ATPase. Membranes
expressing Na+,K+-ATPase were pre-incubated with 50 mM Tris–acetic acid (pH 7.0)
100 mM NaCl and 1.25 mM MgCl2 at 0 °C for 30 min. Then, 0.1 μM radiolabeled
ATP was added for 10 s before the reaction was stopped. Values are presented as
mean ± SEM with N ≥ 3. *p b 0.05 versus mock, ANOVA with Dunnett's post test.
Fig. 6. (A)Ouabain-binding capacity ofwild type andmutantNa+,K+-ATPase.Membranes
were incubated at room temperature in the presence of 50mMhistidine at pH7.0, 10mM
MgCl2, 5 mM H3PO4, 25 nM radiolabeled ouabain and different concentrations of non-
radiolabeled ouabain. Values are presented as mean ± SEM with N ≥ 3. Three mutants
(I274N, E815K and G947R) did not bind ouabain and are not shown. (B) The effect of
K+ on ouabain binding. Membranes were incubated at room temperature in the presence
of 50 mM histidine at pH 7.0, 10 mMMgCl2, 5.0 mM H3PO4, 25 nM radiolabeled ouabain
and increasing concentrations of KCl for 2 h. Values are presented as mean ± SEM with
N ≥ 3, corrected for values obtained in the absence of KCl.
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As described above, threemutants (S137Y, D220N andD801N)were
able to bind ouabain (Fig. 6A), whereas only one of them (D220N)
showed ATPase activity (Fig. 3). In order to determine whether the
K+-binding was affected, we studied the well-known antagonism
between K+ and ouabain (Fig. 1A). We measured the relative oua-
bain binding at increasing concentrations of KCl in the presence of
25 nM ouabain: a decrease in ouabain binding was seen for wild
type and mutant D220N upon increasing KCl concentrations
(Fig. 6B). The inhibitory effect of KCl on ouabain binding was not
observed for S137Y and D801N, indicating that K+ is not able to
bind to these mutants.
3.7. In silico analysis of mutants
In silico analysis of three crystal structures representing α1β1 Na+,
K+-ATPase in various conformations (E1P–ADP, E2P–ouabain, and
E2·2K+·Pi) resulted in the identiﬁcation of various H-bond interactions
involving the residues corresponding to Ser137 and Glu815. In the
E2P–ouabain crystal structure, Ser137 was predicted to form a hydrogen
bondwith Gln85, whereas Glu815 was involved in a network of H-bonds
involving residues Asn761, Lys928, Asn937, and Asn941 in multiple crystal
structures. Finally, Gly947 was observed to have a limited space due to
the close proximity of Val807 and Pro808 as observed for the E2P–ouabain
conformation.
4. Discussion
Alternating Hemiplegia of Childhood (AHC) is a rare, severe
neurodevelopmental disorder caused by de novo mutations in the
ATP1A3 gene, coding for the α3-isoform of Na+,K+-ATPase. In this
study we examined the functional consequences of six single muta-
tions in ATP1A3 associated with AHC. The amino acids affected in
all six mutations are highly conserved in Na+,K+-ATPase, suggesting
an important impact of themutations on enzyme function [27]. Here,
we discuss the relationship between functional activities of the
mutants and the AHC phenotype. A summary of the experimental
ﬁndings obtained for the mutants and wild type Na+,K+-ATPase is
shown in Table 1.
4.1. D220N possesses biochemical characteristics similar to wild
type enzyme
In general, AHCmutations are located near or inside oneof the trans-
membrane domains. One exception to this rule appears to be D220N,
located in the cytosolic loop between transmembrane domains 2 and
3 (Fig. 1B).We could not identify any statistically signiﬁcant differences
between D220N and the wild type enzyme. Protein expression, ATPase
activity, apparent Na+, K+, and ATP afﬁnities, phosphorylation, ouabain
binding, as well as the ouabain/K+ antagonismwere all similar to those
of wild type enzyme. These results imply that this mutation is possibly
not pathogenic, although we have not investigated protein localization.
Further studies are required to explain the severe phenotype reported
for this mutation [8].
4.2. Catalytic activity
All six ATP1A3mutants were expressed at protein levels comparable
to that of wild type enzyme. However, no signiﬁcant ATPase activity or
phosphorylation level was detected for S137Y, I274N, D801N, E815K
and G947R. Moreover, I274N, E815K, and G947R could not bind
ouabain, which indicates that these mutations result in a severely
affected protein with a complete loss of function.
Whereas almost all AHC-linked mutations are de novo, I274N was
reported in a family with several members suffering from a form of
Table 1
Summary of catalytic properties of wild type and mutant Na+,K+-ATPase. Data represent the mean ± SEM of three enzyme preparations corrected for background values.
ATPase activity studies Ouabain binding studies Phosphorylation
ATPase activity
μmol Pi mg−1 h−1
Na+ K0.5
mM
K+ K0.5
mM
ATP K0.5
μM
Max. binding
pmol mg−1 protein
Ouabain Kd
nM
K+/ouabain antagonism
IC50 (mM)
Wild type 0.94 ± 0.11* 11 ± 1 0.62 ± 0.1 55 ± 19 1.55 ± 0.20* 17 ± 5 2.7 ± 1.1 1.42 ± 0.10*
S137Y −0.12 ± 0.07 – – 1.01 ± 0.17* 37 ± 10 » 0.07 ± 0.05
D220N 0.71 ± 0.05* 12 ± 1 0.56 ± 0.1 86 ± 27 1.53 ± 0.16* 27 ± 5 2.9 ± 1.2 1.43 ± 0.06*
I274N 0.07 ± 0.03 – – – Not converged – – 0.21 ± 0.06
D801N −0.03 ± 0.06 – – – 6.62 ± 2.58* 54 ± 31 » −0.03 ± 0.04
E815K −0.07 ± 0.02 – – – Not converged – – 0.05 ± 0.08
G947R −0.09 ± 0.06 – – – −0.02 ± 0.01 – – 0.07 ± 0.11
– = not determined, * = p b 0.05 vs mock, » = exceeding tested range.
1015K.M. Weigand et al. / Biochimica et Biophysica Acta 1842 (2014) 1010–1016alternating hemiplegia [8]. Kirshenbaum et al. modeled the structure
of Na+,K+-ATPase with I274N, which showed a loss of interaction
between Glu776 with its interacting K+ atom and also a disturbance of
the side-chain interaction between Thr272 and Ile274 [12]. These changes
might seriously impact protein functionality, thereby explaining the
lack of ATPase activity.
The absence of ATPase activity in mutant E815K was reported
previously in a study using COS-7 cells [8]. In three crystal structures,
representing the E1P–ADP, E2P–ouabain and E2·2K+·Pi conforma-
tions (4HQJ [24], 4HYT [25] and 2ZXE [26], respectively), we could
identify an extensive interaction network between the side chains
of Glu815 with Asn761, Lys928, Asn937 and Asn941, which is possibly
affected by replacement of the negatively charged glutamic acid by
a positively charged lysine.
Mutant G947R is located in transmembrane domain 9. Being located
in an α-helix, a change from glycine to arginine might strongly disturb
the helix structure. Based on a crystal structure representing the
E2P–ouabain conformation (4HYT [25]), we found that the side
chain of arginine at this position has limited space, as residues
Val807 and Pro808 (in transmembrane domain 6) are located near
Gly947. Also, Gly947 is located close to Glu951, important in regulating
the C-terminal ion pathway [28]. In addition, a recently published
crystal structure of the Na+-bound state suggested that G947R af-
fects the IIIa ion binding site of Na+,K+-ATPase, which is important
for the release of Na+ ions following transition from the E1P–ADP
state to the E2P state [24].
4.3. Ouabain and K+ binding
S137Y andD801N failed to showATPase activity,whereas signiﬁcant
ouabain binding was present. We conclude that these two mutations
result in a correctly folded protein, capable of binding ouabain, yet
with an impaired reaction cycle. It appeared that they can transit into
the ouabain binding E2P conformation, indicating that the conformation
that is affected involves the Na+ binding E1 state. The absence of phos-
phorylated protein also points in this direction, as ATP phosphorylation
occurs via the E1 state of the enzyme.
The ouabain binding capacity of these mutants allows us to evaluate
the K+ binding capacity. It is known that ouabain and K+ act as antago-
nists, and a change in K+ afﬁnity should therefore be reﬂected by a shift
in the K+/ouabain competition curve. Although the amount of ouabain
bound enzyme was decreased for wild type and D220N, we could not
observe this phenomenon for S137Y and D801N. This indicates that
the latter mutations decrease the afﬁnity for K+, which together with
the absence of phosphorylation suggest that S137Y and D801N affect
cation binding in general.
Whereas this study reports on the biochemical effects of the S137Y
mutation, low ATPase activity for S137F was reported before in COS-7
cells [8]. Ser137 is located within the second transmembrane domain
where it forms an H-bond with Gln85 as based on our in silico analysisof the recently published E2P–ouabain structure [25]. Gln85 is located
just before the characteristic TM1 kink, important in the N-terminal
ion pathway of the enzyme [29], through which the cations pass.
Replacing the serine with a tyrosine might have a strong impact on
the interaction between serine and glutamine, due to the bulky aromatic
ring in the side chain of tyrosine.
Mutant D801N belongs to the most frequent mutations in AHC
cases [8,9]. This mutation has been reported to reduce ATPase activity
in COS-7 cells [8], in accordance with our results. In addition, we have
previously shown a lack of phosphorylation for the corresponding
residue (Asp804) in rat α1 Na+,K+-ATPase [30]. Contrary to our results,
Pedersen et al. described the phosphorylation of mutant D804N after
Na+ stimulation in yeast cells [31]. Structural modeling of the D801N
mutation predicted a direct effect on binding of potassium ions [8,12],
reﬂecting the highly important role of Asp801 in coordination of ion
binding sites I and II in K+-occlusion [32] and Na+-coordination [24,
33], and also binding of a Mg2+ ion in site II in the high resolution
ouabain bound structure [25]. We speculate that replacing aspartic
acid with asparagine at this position increases the preference of the
enzyme for the E2P-DLC conformation by decreasing the preference
for the E2P conformation. For rat Na+,K+-ATPase α1 it was already
known that Asp804 (corresponding to Asp801 in human) plays a major
role in the cation binding pocket [31,34].
4.4. Mechanism of disease
Unfortunately, the exact mechanism of disease for ATP1A3 muta-
tions remains to be understood. It is known that the alpha 3 subunit of
Na+,K+-ATPase is found mainly in the central and peripheral nervous
system, and therefore it is not surprising that these mutations have a
neurological effect. The ﬁrst study to look at the functional consequences
of AHC at the cellular level was published recently [35], reporting a struc-
tural and functional granule defect in platelets and ﬁbroblasts of AHC
patients. Furthermore, increased cathepsin B-dependent apoptosis
in ﬁbroblasts was observed, linking lysosomal defects to decreased
ATPase activity.
It is highly challenging to correlate changes in biochemical charac-
teristics to the frequency and duration of attacks in patients suffering
from AHC. However, due to the high frequency of D801N and E815K,
responsible for most AHC cases, it was possible to show that E815K
causes a more severe phenotype than D801N [10]. Although both
enzymes are catalytically inactive, we found that D801N is able to
bind ouabain, whereas E815K is not. Possibly, the lack of ouabain bind-
ing might link E815K to its severe phenotype. Previous studies have
shown that ouabain and other digitalis-like compounds are produced
endogenously, both in adrenal cells as well as in the hypothalamus
[36]. The role of Na+,K+-ATPase as a signal transducer might provide
an explanation for the less severe phenotype observed for mutation
D801N compared with mutation E815K. A possible role of endogenous
ouabain in AHC should be the subject of future studies.
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Our study is the ﬁrst to show in detail the biochemical properties of
six AHC causing mutations, and reveals that mutations in ATP1A3 affect
the functionality of Na+,K+-ATPase, which might explain why they are
associated with AHC. However, no differences in protein function were
observed for mutant D220N compared to wild type Na+,K+-ATPase.
Mutants I274N, E815K, and G947R did not result in functional protein
as reﬂected by a complete loss of ouabain binding and ATPase activity,
rendering them unsuitable for further studies. Mutants S137Y and
D801N could bind ouabain, but showed no ATPase activity, no phos-
phorylation, and an impaired K+ binding. The presence of ouabain
binding might provide an explanation for the less severe phenotype
observed for D801N as compared to E815K.
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